Topic / Pathology
- Stroke
- Thrombolysis
Objectives
To test the hypothesis that the thrombolytic tenecteplase (TNK, 0.25mg/kg) administered within 24 hours after symptom onset ± thrombectomy, is superior to current best practice (alteplase, rtPA, 0.9mg/kg within 4.5 hours of stroke onset or standard care/no lysis ± thrombectomy) in achieving excellent functional outcome (mRS 0-1) or return to the premorbid modified Rankin Scale at 90 days in patients with acute ischaemic stroke due to basilar artery occlusion.
Sponsor
CHRU de Tours
Investigator
Pr Marco Pasi
Status
Forthcoming
